2023
Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases.
Chan N, Einstein A, Griffin J, Rosenblum H, Teruya S, Cuomo M, De Los Santos J, DeLuca A, Johnson L, Kinkhabwala M, Leb J, Mintz A, Fine D, Helmke S, Muralidhar V, Pandey S, Sabogal N, Saith S, Winburn M, Smiley D, Miller E, Ruberg F, Maurer M. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases. Journal Of Nuclear Cardiology 2023, 30: 2531-2539. PMID: 38245059, DOI: 10.1007/s12350-023-03310-7.Peer-Reviewed Original ResearchConceptsTc-99m PYP uptakeExtracardiac uptakeATTR-CACardiac amyloidosisClinically actionable findingsDiagnose transthyretin cardiac amyloidosisTc-99Transthyretin cardiac amyloidosisBone uptakeTime of scanningBreast uptakeTc-99m PYP imagingThyroid uptakeHeart failureBlack raceRenal uptakeNuclear imagingPyrophosphate imagingTechnetium pyrophosphateHispanic ethnicityHispanic participantsNuclear scintigraphyMinority populationsClinicSelf-identifyPrevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases
Chan N, Einstein A, Griffin J, Rosenblum H, Teruya S, Cuomo M, De Los Santos J, DeLuca A, Johnson L, Kinkhabwala M, Leb J, Mintz A, Fine D, Helmke S, Muralidhar V, Pandey S, Sabogal N, Saith S, Winburn M, Smiley D, Miller E, Ruberg F, Maurer M. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases. Journal Of Nuclear Cardiology 2023, 30: 2531-2539. PMID: 37311914, DOI: 10.1007/s12350-023-03310-7.Peer-Reviewed Original ResearchConceptsExtracardiac uptakePYP uptakeCardiac amyloidosisBone uptakeActionable findingsTiming of scansTransthyretin cardiac amyloidosisHeart failureBreast uptakeMean ageBlack raceRenal uptakeHispanic ethnicityThyroid uptakeATTR-CANuclear scintigraphyHispanic participantsTechnetium pyrophosphateNuclear imagingPYP scanPopulation studiesSelf-identified BlackAdditional testingAmyloidosisSubjectsDiagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study
Pandey S, Teruya S, Rodriguez C, Deluca A, Kinkhabwala M, Johnson L, Fine D, Sabogal N, Winburn M, Castillo M, Bhatia K, Malkovskaya R, Raiszadeh F, Kurian D, Miller E, Einstein A, Maurer M, Ruberg F. Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study. Journal Of Nuclear Cardiology 2023, 30: 1414-1419. PMID: 36823486, PMCID: PMC11268194, DOI: 10.1007/s12350-023-03203-9.Peer-Reviewed Original ResearchConceptsTransthyretin cardiac amyloidosisATTR-CACardiac amyloidosisLow pretest probabilityLow pretest likelihoodLV wall thicknessDiagnostic performance characteristicsPositive predictive valueNon-invasive diagnosisConclusionAmong patientsMinority older adultsHeart failurePretest likelihoodPretest probabilitySemi-quantitative parametersPYP uptakeImportant misclassificationPredictive valueImaging thresholdsOptimal heartOlder adultsDiagnostic performancePatientsReference standardScans
2022
Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement
Miller EJ, Campisi R, Shah NR, McMahon S, Cuddy S, Gallegos-Kattan C, Maurer MS, Damy T, Slart RHJA, Bhatia K, Einstein AJ. Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement. Journal Of Nuclear Cardiology 2022, 29: 2748-2760. PMID: 35838892, PMCID: PMC9285188, DOI: 10.1007/s12350-022-03059-5.Peer-Reviewed Original Research
2016
Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis
Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, Pozniakoff T, Ruberg FL, Miller EJ, Berk JL, Dispenzieri A, Grogan M, Johnson G, Bokhari S, Maurer MS. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiology 2016, 1: 880-889. PMID: 27557400, DOI: 10.1001/jamacardio.2016.2839.Peer-Reviewed Original ResearchConceptsATTR cardiac amyloidosisCardiac amyloidosisMulticenter studyWorse survivalEjection fractionHeart failureCardiac imagingMultivariable Cox proportional hazards regression analysisCox proportional hazards regression analysisProportional hazards regression analysisRetrospective cohort studyHigh clinical suspicionSingle-center studyHazards regression analysisKaplan-Meier analysisAL cardiac amyloidosisDifferentiation of patientsTransthyretin cardiac amyloidosisDates of analysisSemiquantitative visual scoreContralateral chestPlanar technetiumClinical suspicionCohort studyPrognostic importance